May 27. 2015 – NeoStem, Inc. (Nasdaq:NBS) (“NeoStem” or the “Company”), announced today the pricing of an underwritten public offering of 12,500,000 shares of common stock at a public offering price of $2.00 per share. The gross proceeds to NeoStem from this offering are expected to be approximately $25,000,000 before deducting underwriting discounts and commissions and other estimated offering expenses payable by the Company. The Company has granted the underwriter a 45-day option to purchase up to an aggregate of 1,875,000 additional shares of its common stock to cover over-allotments, if any. The Company intends to use the net proceeds from this offering for working capital, including research and development of cell therapeutic product candidates, especially its lead immuno-oncology program, NBS20, expansion of business units, strategic transactions and other general corporate purposes. The offering is expected to close on or about June 2, 2015, subject to the satisfaction of customary closing conditions.
Maxim Group acted as a financial advisor for NeoStem’s $25.0 million follow-on offering.